Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ESPRNASDAQ:GHRSNASDAQ:KZRNASDAQ:VERU Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$1.99-6.6%$2.42$0.70▼$3.40$376.91M0.846.65 million shs200,175 shsGHRSGH Research$10.50-5.2%$9.97$5.05▼$14.64$546.32M0.8496,352 shs32,083 shsKZRKezar Life Sciences$0.80+1.3%$0.89$0.67▼$3.13$58.25M0.47684,533 shs400 shsVERUVeru$1.23+1.7%$0.82$0.36▼$1.92$180.05M-0.212.34 million shs19,622 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics-6.57%+6.42%-26.30%-6.57%+64.46%GHRSGH Research-5.23%-6.17%-5.32%+44.83%+31.74%KZRKezar Life Sciences-1.42%+0.30%-11.62%-4.76%-66.67%VERUVeru-8.33%-14.79%+98.39%+181.33%-5.47%How a $0.25 cent option contract makes my top traders feel (Ad)If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all aboutMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESPREsperion Therapeutics4.1344 of 5 stars3.24.00.03.93.40.80.6GHRSGH Research1.5078 of 5 stars3.51.00.00.02.32.50.0KZRKezar Life Sciences3.5101 of 5 stars3.21.00.04.60.61.71.3VERUVeru1.3319 of 5 stars3.41.00.00.02.91.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESPREsperion Therapeutics2.40Hold$9.33369.01% UpsideGHRSGH Research3.00Buy$39.50276.19% UpsideKZRKezar Life Sciences2.33Hold$11.001,274.83% UpsideVERUVeru2.75Moderate Buy$3.33171.00% UpsideCurrent Analyst RatingsLatest ESPR, KZR, VERU, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024VERUVeruOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.004/10/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/28/2024VERUVeruRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/25/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/25/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/4/2024GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/1/2024GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $39.002/28/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $16.002/27/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.002/8/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESPREsperion Therapeutics$116.33M3.24N/AN/A($3.85) per share-0.52GHRSGH ResearchN/AN/AN/AN/A$4.94 per shareN/AKZRKezar Life Sciences$7M8.32N/AN/A$2.58 per share0.31VERUVeru$16.30M11.05N/AN/A$0.22 per share5.59Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESPREsperion Therapeutics-$209.25M-$2.12N/A6.42N/A-179.87%N/A-91.62%5/7/2024 (Confirmed)GHRSGH Research-$35.59M-$0.68N/AN/AN/AN/A-15.48%-15.01%5/9/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)VERUVeru-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/9/2024 (Estimated)Latest ESPR, KZR, VERU, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AESPREsperion Therapeutics-$0.17N/A+$0.17N/AN/AN/A 4/1/2024Q1 2024VERUVeruN/A-$0.09-$0.09-$0.10N/A$2.14 million3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/A2/29/2024Q4 2023GHRSGH Research-$0.20-$0.21-$0.01-$0.21N/AN/A2/27/202412/31/2023ESPREsperion Therapeutics-$0.53-$0.50+$0.03-$0.50$26.84 million$32.25 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESPREsperion TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESPREsperion TherapeuticsN/A1.290.87GHRSGH ResearchN/A24.4924.49KZRKezar Life Sciences0.0511.6611.66VERUVeruN/A3.212.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESPREsperion Therapeutics47.39%GHRSGH Research56.90%KZRKezar Life Sciences67.90%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipESPREsperion Therapeutics1.00%GHRSGH Research41.60%KZRKezar Life Sciences7.90%VERUVeru14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableESPREsperion Therapeutics240189.40 million187.51 millionOptionableGHRSGH Research4952.03 million30.38 millionOptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableVERUVeru189146.38 million125.60 millionOptionableESPR, KZR, VERU, and GHRS HeadlinesSourceHeadlineVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11globenewswire.com - April 25 at 8:30 AMNetflix To Stop Sharing Subscriber Data; Stock Dipsmarkets.businessinsider.com - April 19 at 6:13 PMWhat Makes Veru (VERU) a New Buy Stockzacks.com - April 17 at 1:01 PMVeru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimeramericanbankingnews.com - April 16 at 3:26 AMVeru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimermarketbeat.com - April 15 at 8:29 AMREVEALED: Transport Malta officials at centre of maritime fines corruption racketmaltatoday.com.mt - April 2 at 12:43 AMVeru Announces Date of 2024 Annual Meeting of Shareholdersfinance.yahoo.com - April 1 at 7:43 PMFlag carrier Air Malta ceases operations today, its 50th birthdaymaltatoday.com.mt - March 31 at 6:39 PMVeru Incmorningstar.com - March 29 at 9:35 PMUpdated | Mosta trees vandalised: ERA, police investigatingmaltatoday.com.mt - March 29 at 8:54 AMRaymond James Begins Coverage on Veru (NASDAQ:VERU)marketbeat.com - March 28 at 8:28 AMR&B Realty’s Gateway at Wynwood hit with foreclosure lawsuittherealdeal.com - March 22 at 6:18 PMVeru Reschedules Annual Meeting of Shareholdersglobenewswire.com - March 22 at 4:05 PMWynwood offices targeted in $102M foreclosurebizjournals.com - March 21 at 6:43 PMNaksha Saran plays a bike taxi driver in her next filmmsn.com - March 19 at 4:27 AMPrecise and efficient cutting (sawing) of lightweight core materialsjeccomposites.com - March 18 at 1:24 PMVERU Mar 2024 0.500 putca.finance.yahoo.com - March 16 at 1:30 PMVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Lossglobenewswire.com - March 12 at 8:00 AMVERU Mar 2024 1.500 putfinance.yahoo.com - March 11 at 11:33 PMBrussels is mixed bag of emotions on possible Joseph Muscat returnmaltatoday.com.mt - March 11 at 1:32 PMVERU Jan 2025 17.000 callfinance.yahoo.com - March 9 at 6:52 PMVERU Mar 2024 0.500 callfinance.yahoo.com - March 9 at 1:52 PMVERU Mar 2024 3.000 putfinance.yahoo.com - March 9 at 1:52 PMVERU Mar 2024 2.500 putfinance.yahoo.com - March 1 at 11:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEsperion TherapeuticsNASDAQ:ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.GH ResearchNASDAQ:GHRSGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.VeruNASDAQ:VERUVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.